FTM Low-Dose and Nonbinary

Not everyone wants full, fast masculinization. Some nonbinary and genderqueer people (and some trans men) want slower changes, fewer changes, or a short course of T to “bank” certain permanent effects and then stop. All of those are valid goals. This page covers what low-dose testosterone is, what it realistically can and can’t do.

You have the right to an individualized plan

WPATH SOC8 Chapter 8 (Nonbinary) is explicit: clinicians should “provide nonbinary people with individualized assessment and treatment that affirms their experience of gender,” and should consider hormones and surgery “in the absence of ‘social gender transition.‘”¹ You don’t have to want a binary transition, a standard dose, or every effect, to be offered care. Good clinicians will ask about your embodiment goals such as which specific changes, to which specific body parts, would be affirming rather than “masculinization” as a package deal.²

What “low-dose” actually means

There’s no agreed definition of “microdosing” as it’s a community term, not a clinical one.² In practice, low-dose regimens look like UCSF’s “Initial - low dose” tier in its masculinizing therapy guideline, which the guideline itself describes as “recommended for genderqueer and nonbinary dosing”:³

Injections: ~20 mg/week testosterone cypionate or enanthate (the two common injectable forms of T) (vs 50-100 mg/week standard)
Gel: 12.5-25 mg/day (vs 50-100 mg/day standard)

Some people deliberately maintain testosterone levels in an intermediate range between typical female and male ranges.³ The usual strategy is “start low, titrate slowly to effect”. titrating just means adjusting the dose gradually, guided by your goals, your levels, and how your body responds.³

The evidence is nearly nonexistent

Be skeptical of anyone who claims certainty here, in either direction:

The only cohort study (a study following a group of people over time) of low-dose T in nonbinary people (Nolan et al., ENDO 2024, n=46 using transdermal T, meaning gel or patches, median level ~11 nmol/L) found 87% were still on low-dose at ~14 months, 13% escalated to full dose, and 3 people (7%) developed polycythemia (too many red blood cells). Physical outcomes were not measured at all so we don’t actually know how much slower or lesser changes were.⁴
No randomized trial of low-dose testosterone has ever been completed. A randomized trial (RCT) is the gold-standard study type, where people are randomly assigned a regimen. The first one (measuring dysphoria, euphoria, and mental health) is still recruiting at Austin Health, Melbourne.⁵ A small retrospective audit (looking back at clinic records) (Ward-Smith 2026) and one youth review round out the literature; an NHS England evidence review found zero eligible studies for nonbinary partial masculinization in under-18s.⁶
Everything else is expert extrapolation (careful guesswork) from binary-transition and cis-puberty data. Even the 2024 expert review by Dimakopoulou & Seal states plainly that regimens “have not been examined by randomised controlled clinical trials.”⁷

What low-dose does and doesn’t do

It slows changes down. That’s the one consistent expectation. the same menu of effects, arriving more gradually (and possibly to a lesser final degree but “slower vs lesser” is unresolved until trials report).⁴⁷

It does NOT reliably spare your voice. This is the most important myth to kill. The larynx responds at moderate testosterone levels, avoiding voice change would require keeping levels very low, below ~7 nmol/L, which is barely above typical pre-T levels.⁷ Voice F0 (pitch) drops don’t track serum (blood) androgen levels, and community reports confirm even microdoses can permanently deepen the voice.⁸ If preserving your voice is a priority, the strategies experts discuss are limiting duration (stopping before the voice “breaks,” usually 6-12 months in) or simply not taking T not low doses.⁷ See Voice Training for non-hormonal options.

It usually won’t stop your periods. Lower doses frequently don’t suppress menstruation so if stopping bleeding is a goal, you’ll likely need an add-on (see below).⁷⁹

You cannot pick and choose effects. At any dose. SOC8: “if facial hair development is needed, genital growth is inevitable” and the timeframe that produces hair changes usually brings an irreversible voice drop too.¹ UCSF: “it is not possible to prospectively choose a regimen that will predictably allow patients to arrive at a specified configuration of sex characteristics.”³ Bottom growth and libido (sex drive) increase are near-universal; breast/chest tissue is not meaningfully reduced by T at any dose.⁷

Tools people combine with (or use instead of) low-dose T

Finasteride/dutasteride (blockers of DHT, a stronger hormone made from testosterone): proposed to keep voice + muscle changes while reducing facial/body hair and scalp hair loss. The trade-off cuts both ways: DHT also drives bottom growth, and SOC8 warns 5α-reductase inhibitors “may impair clitoral growth and the development of facial and body hair.”¹ Higher doses risk “regression of some virilization” and sexual side effects (UCSF).³ Net effect on overall virilization (masculinization) in trans men is unknown. ¹⁰
Menstrual suppression without T: progestins (progesterone-like hormones such as norethindrone/norethisterone or medroxyprogesterone), GnRH agonists (medications that switch off the ovaries’ hormone signals), a levonorgestrel IUD (a hormone-releasing device placed in the uterus), or the implant are standard options, used with or without T. Irregular bleeding is common in the first months; long-term DMPA (the 3-monthly injection) carries a bone-density caution.⁹¹¹ (Note: norethisterone is sometimes avoided because it can aromatize to ethinylestradiol, a type of estrogen.⁷)
Minoxidil for facial hair: one trans-specific case report + one 16-person cohort + one cis RCT. see FTM Community Knowledge for more information.

Stopping, pausing, and time-limited courses

If you stop T and still have your ovaries, SOC8 Chapter 8 describes what reverts and what persists:¹

Persists (permanent)	Reverts toward baseline
Voice deepening	Periods return (usually 3-6 months)
Facial/body hair follicles	Fat redistribution
Bottom growth	Muscle mass & strength
Male-pattern scalp hair loss	Skin oiliness/acne, libido shifts, body-hair rate

A planned, continuous, time-limited course (e.g., 6-12 months) to acquire irreversible changes and then stop is a clinically recognized strategy, UCSF describes it explicitly, but it is lacking in evidence, and the effects you get before stopping are luck of the genetic draw.³²

Monitoring on a low dose

SOC8 notes the implications of long-term low-dose therapy are undocumented and advises considering cardiovascular (heart and blood vessel) and bone health monitoring. sex hormones protect bone, and intermediate levels sit below the usual protective range.¹ Expert reviewers suggest DEXA scanning (a low-radiation scan that measures bone density) every 3-5 years plus lipid checks (blood fats like cholesterol) for people maintained below male-range levels.⁷ Hematocrit (your red-blood-cell level) still applies (7% polycythemia in the Nolan cohort even at low dose).⁴ See FTM Blood Testing.

The Trans Directory

Explorer

FTM Low-Dose and Nonbinary

You have the right to an individualized plan

What “low-dose” actually means

The evidence is nearly nonexistent

What low-dose does and doesn’t do

Tools people combine with (or use instead of) low-dose T

Stopping, pausing, and time-limited courses

Monitoring on a low dose

Further reading

Graph View

Table of Contents

Backlinks

The Trans Directory

Explorer

FTM Low-Dose and Nonbinary

You have the right to an individualized plan

What “low-dose” actually means

The evidence is nearly nonexistent

What low-dose does and doesn’t do

Tools people combine with (or use instead of) low-dose T

Stopping, pausing, and time-limited courses

Monitoring on a low dose

Further reading

Footnotes

Graph View

Table of Contents

Backlinks